If you’re flirting with the idea of taking CBD oil for ulcerative colitis, this article will give you a detailed look into the scientific research on this subject on top of sharing some handy tips for using CBD.
According to the National Institute of Health, CBD has both analgesic (pain-relieving) and anti-inflammatory effects on the gastrointestinal tract without causing intoxication.
What Is Ulcerative Colitis?
Here are the most common ways people take CBD for ulcerative colitis:
However, studies also show that the anti-inflammatory and analgesic effects of CBD are enhanced when you introduce some THC to an extract (along with other cannabinoids and terpenes). Researchers argue that even 1% of THC in a cannabis strain can significantly improve the plant’s therapeutic potential.
Now that we’ve established CBD can help with ulcerative colitis, you’re probably wondering if it can have similar effects on Crohn’s disease. After all, this condition, too, belongs to the IBD group.
Two RCTs (92 participants) met the inclusion criteria. One study (N = 60) compared 10 weeks of cannabidiol capsules with up to 4.7% D9-tetrahydrocannabinol (THC) with placebo capsules in participants with mild to moderate UC. The starting dose of cannabidiol was 50 mg twice daily increasing to 250 mg twice daily if tolerated. Another study (N = 32) compared 8 weeks of therapy with two cannabis cigarettes per day containing 0.5 g of cannabis, corresponding to 23 mg THC/day to placebo cigarettes in participants with UC who did not respond to conventional medical treatment. No studies were identified that assessed cannabis therapy in quiescent UC. The first study was rated as low risk of bias and the second study (published as an abstract) was rated as high risk of bias for blinding of participants and personnel. The studies were not pooled due to differences in the interventional drug.
Cannabis and cannabinoids are often promoted as treatment for many illnesses and are widely used among patients with ulcerative colitis (UC). Few studies have evaluated the use of these agents in UC. Further, cannabis has potential for adverse events and the long-term consequences of cannabis and cannabinoid use in UC are unknown.
Cannabis is a widely used recreational drug that has multiple effects on the body via the endocannabinoid system. Cannabis contains multiple sub-ingredients called cannabinoids. Cannabis and cannabis oil containing specific cannabinoids can cause cognitive changes such as feelings of euphoria and altered sensory perception. However, some cannabinoids, such as cannabidiol, do not have a psychoactive effect. Cannabis and some cannabinoids have been shown to decrease inflammation in animal and laboratory models which suggests it may help people with ulcerative colitis. For example, cannabidiol is one such cannabinoid that has shown anti-inflammatory activity in mice.
We searched MEDLINE, Embase, WHO ICTRP, AMED, PsychINFO, the Cochrane IBD Group Specialized Register, CENTRAL, ClinicalTrials.Gov and the European Clinical Trials Register from inception to 2 January 2018. Conference abstracts and references were searched to identify additional studies.
What did the researchers investigate?
The effect of cannabidiol capsules (100 mg to 500 mg daily) compared to placebo on clinical remission and response is uncertain. Clinical remission at 10 weeks was achieved by 24% (7/29) of the cannabidiol group compared to 26% (8/31) in the placebo group (RR 0.94, 95% CI 0.39 to 2.25; low certainty evidence). Clinical response at 10 weeks was achieved in 31% (9/29) of cannabidiol participants compared to 22% (7/31) of placebo patients (RR 1.37, 95% CI 0.59 to 3.21; low certainty evidence). Serum CRP levels were similar in both groups after 10 weeks of therapy. The mean CRP in the cannabidiol group was 9.428 mg/L compared to 7.638 mg/L in the placebo group (MD 1.79, 95% CI -5.67 to 9.25; moderate certainty evidence). There may be a clinically meaningful improvement in quality of life at 10 weeks, measured with the IBDQ scale (MD 17.4, 95% CI -3.45 to 38.25; moderate certainty evidence). Adverse events were more frequent in cannabidiol participants compared to placebo. One hundred per cent (29/29) of cannabidiol participants had an adverse event, compared to 77% (24/31) of placebo participants (RR 1.28, 95% CI 1.05 to1.56; moderate certainty evidence). However, these adverse events were considered to be mild or moderate in severity. Common adverse events included dizziness, disturbance in attention, headache, nausea and fatigue. None (0/29) of the cannabidiol participants had a serious adverse event compared to 10% (3/31) of placebo participants (RR 0.15, 95% CI 0.01 to 2.83; low certainty evidence). Serious adverse events in the placebo group included worsening of UC and one complicated pregnancy. These serious adverse events were thought to be unrelated to the study drug. More participants in the cannabidiol group withdrew due to an adverse event than placebo participants. Thirty-four per cent (10/29) of cannabidiol participants withdrew due to an adverse event compared to 16% (5/31) of placebo participants (RR 2.14, 95% CI 0.83 to 5.51; low certainty evidence). Withdrawls in the cannabidiol group were mostly due to dizziness. Withdrawals in the placebo group were due to worsening UC.
The effects of cannabis and cannabidiol on UC are uncertain, thus no firm conclusions regarding the efficacy and safety of cannabis or cannabidiol in adults with active UC can be drawn.There is no evidence for cannabis or cannabinoid use for maintenance of remission in UC. Further studies with a larger number of patients are required to assess the effects of cannabis in UC patients with active and quiescent disease. Different doses of cannabis and routes of administration should be investigated. Lastly, follow-up is needed to assess the long term safety outcomes of frequent cannabis use.
CBD oil, which has become the most popular form of CBD as a therapy, is essentially a natural extract from raw cannabis plant material. It can come from actual strains of marijuana (which contain THC), or from industrial hemp, which is similar to marijuana but contains less than .3% THC.
As we’ve mentioned, ulcerative colitis is defined as persistent inflammation of the colon, aka the large intestine. This chronic inflammation may range from mild to severe, and in the latter instances, it is common for the colon’s inner lining to develop painful lesions, sores, and other forms of irritation.
What Is Ulcerative Colitis – And How Is It Typically Treated?
Regardless, it’s important to point out that the majority of top U.S. CBD oil manufacturers are shipping to all 50 states. No matter what part of the country you live in, it is easy to order online and have the product shipped to your home.
Current sufferers of UC will know that conventional pharmaceutical medications for the disorder are both costly and may have dangerous side effects. As such, many have been actively seeking alternative forms of treatment, with CBD appearing as one possible option.
It’s important to note, however, that symptoms of ulcerative colitis are non-persistent in nature; a victim may go several weeks or even months with no symptoms at all, only to experience a severe flare-up seemingly out of nowhere.